Found: 20
Select item for more details and to access through your institution.
Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.
- Published in:
- Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2013, v. 6, p. 171, doi. 10.2147/DMSO.S41827
- By:
- Publication type:
- Article
The Real‐World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient‐reported outcomes at 24 months.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3453, doi. 10.1111/dom.15145
- By:
- Publication type:
- Article
The real‐world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24‐month analysis of time to first significant treatment change, treatment persistence and clinical outcomes
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3465, doi. 10.1111/dom.15244
- By:
- Publication type:
- Article
T he R eal‐World O bservational P rospective Study of H ealth Outcomes with Dulaglut i de and Liraglutide in Patients with Typ e 2 Diabete s (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 12, p. 2373, doi. 10.1111/dom.14823
- By:
- Publication type:
- Article
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1861, doi. 10.1111/dom.14775
- By:
- Publication type:
- Article
Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2660, doi. 10.1111/dom.13853
- By:
- Publication type:
- Article
Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 12, p. 2660, doi. 10.1111/dom.13853
- By:
- Publication type:
- Article
Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS).
- Published in:
- BMC Psychiatry, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-244X-13-79
- By:
- Publication type:
- Article
Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: The CHOICE prospective.
- Published in:
- Health & Quality of Life Outcomes, 2013, v. 11, n. 1, p. 1, doi. 10.1186/1477-7525-11-217
- By:
- Publication type:
- Article
Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 9, p. 2039, doi. 10.1007/s13300-024-01620-8
- By:
- Publication type:
- Article
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 11, p. 1867, doi. 10.1007/s13300-023-01457-7
- By:
- Publication type:
- Article
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 11, p. 1833, doi. 10.1007/s13300-023-01451-z
- By:
- Publication type:
- Article
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 7, p. 1929, doi. 10.1007/s13300-021-01076-0
- By:
- Publication type:
- Article
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 10, p. 2383, doi. 10.1007/s13300-020-00908-9
- By:
- Publication type:
- Article
GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries.
- Published in:
- Diabetes Therapy, 2017, v. 8, n. 1, p. 115, doi. 10.1007/s13300-016-0224-5
- By:
- Publication type:
- Article
Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.
- Published in:
- Diabetes Therapy, 2013, v. 4, n. 2, p. 285, doi. 10.1007/s13300-013-0037-8
- By:
- Publication type:
- Article
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir.
- Published in:
- Diabetes Care, 2013, v. 36, n. 5, p. 1368, doi. 10.2337/dc12-1333
- By:
- Publication type:
- Article
Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.
- Published in:
- ClinicoEconomics & Outcomes Research, 2013, v. 5, p. 355, doi. 10.2147/CEOR.S44060
- By:
- Publication type:
- Article